Emergent partnered with the USG to supply the nation’s only approved anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). Emergent has gradually grown from a one site, one product company to ...

Emergent’s key Biodefense product, BioThrax, is the sole vaccine approved by the FDA for pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease. In the past year, shares of ...

The US Department of Defense (DoD) has awarded a procurement contract worth up to $235.8m to Emergent BioSolutions for an indefinite-delivery and indefinite-quantity (IDIQ) supply of BioThrax.